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Based on  results of a  transcriptomic analysis performed  in 
human SW480-ADH colon cancer cells that indicated an increase 
































1α,25(OH)2D3 increases cystatin D protein expression by direct activa-



































































Cystatin D inhibits proliferation, migration, and anchorage-independent 
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Figure 1
1α,25(OH)2D3 induces cystatin D expression. (A) Kinetics of CST5 RNA (top) and protein (bottom) induction by 1α,25(OH)2D3. SW480-ADH 
cells were incubated with 1α,25(OH)2D3 (10–7 M) or vehicle for the indicated times, and the levels of CST5 RNA and protein were measured by 
quantitative RT-PCR (top) or Western blotting (bottom) as explained in Methods. Normalized mean values and SD obtained in 3 independent 
experiments are shown. (B) Dose-curve induction of CST5 RNA (top) and protein (bottom) by 1α,25(OH)2D3. Numbers between the blots in 
A and B correspond to mean of the fold increase values obtained in 2 experiments. (C) Immunofluorescence analysis of cystatin D induction. 
Images of SW480-ADH and SW480-R cells treated with 1α,25(OH)2D3 (10–7 M) or vehicle for 48 hours. The relocalization of β-catenin was ana-
lyzed as control of 1α,25(OH)2D3 action. Scale bars: 20 μm. (D) The 1α,25(OH)2D3 analog EB1089 induces cystatin D expression in vivo. Left: 
Immunohistochemical analysis of cystatin D expression in tumors generated by SW480-ADH cells in immunodeficient mice that were treated with 
EB1089 (10–7 M) or placebo. Scale bar: 200 μm. Right: Quantification of cystatin D expression by estimation of staining intensity as described in 
Methods. The number of samples analyzed per group and the percentage corresponding to each level of cystatin D staining are shown.
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Figure 2
1α,25(OH)2D3 directly activates the CST5 promoter. (A) Quantitative RT-PCR analysis of CST5 RNA expression in SW480-ADH cells treated with 
1α,25(OH)2D3 or vehicle that were pretreated for 30 minutes with actinomycin D (2 μg/ml) or cycloheximide (8 μg/ml) as indicated. (B) Scheme 
of the human CST5 gene promoter showing putative VDR binding sites grouped in regions A–D. (C) Activation of CST5 promoter constructs by 
1α,25(OH)2D3 in SW480-ADH cells and in HEK293T cells cotransfected with an expression vector for wild-type VDR. Twenty-four hours after 
transfection, cells were treated with vehicle or 1α,25(OH)2D3 (10–7 M) for an additional 48 hours. The empty pGL3 vector was used as control. 
(D) The activation of the CST5 promoter by 1α,25(OH)2D3 requires a transcriptionally competent VDR. SW480-R cells were cotransfected with 
the promoter construct pGL3-1867 or pGL3-251 and either the wild-type VDR or the mutant ΔAF2-VDR (VDRΔAF2), or an empty vector. The cells 
were then treated with 1α,25(OH)2D3 (10–7 M) or vehicle for 48 hours. As control, the consensus 4xVDRE-DR3-Tk-Luc (VDRE) reporter construct 
was cotransfected with the wild-type or mutant VDR. Values correspond to promoter induction by 1α,25(OH)2D3 in 3 independent experiments 
done in triplicate. (E) 1α,25(OH)2D3 induces VDR binding to and an active chromatin conformation of the CST5 promoter in vivo. ChIP assay 
showing the induction by 1α,25(OH)2D3 of VDR binding, SMRT corepressor release, and increased histone H4 acetylation (AcH4) of the CST5 
gene promoter in SW480-ADH cells. The CYP24 gene was used as control. The promoter regions studied are indicated.
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Cystatin D induces intercellular adhesion proteins and inhibits genes pro-












els of SNAI2, ZEB1, and ZEB2 RNA than empty vector–transfected 
(mock) cells (Figure 7D). In contrast, only a weak reduction in 
SNAI1 and no change in TWIST expression were found.
Cystatin D extends the cell cycle and inhibits Wnt/β-catenin signaling 




Ectopic cystatin D expression inhibits pro-
liferation and alters gene expression in 
SW480-ADH cells. (A) Cystatin D inhibits 
cell proliferation. (B) Quantitative RT-PCR 
analysis showing the level of CYP24, CDH1, 
and LEF1 RNA in cystatin D–expressing 
cells. (C) Western blot analysis showing 
changes in E-cadherin, c-MYC, and LEF-1 
proteins in cystatin D–expressing cells. 
(D) Cystatin D inhibits SNAI1 expression. 
Quantitative RT-PCR (left) and Western blot 
(right) analyses showing reduced SNAI1 
RNA and protein levels in cystatin D– 
expressing cells. Numbers between the 
blots in C and D correspond to mean of the 
fold increase values obtained in 2 experi-
ments. *P < 0.05, **P < 0.01, ***P < 0.001. 
The Western blot in D shows noncontigu-
ous lanes run on the same gel.
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CST5 silencing affects SW480-ADH cell proliferation and gene expression. (A) Phase-
contrast images of control shRNA and CST5 shRNA cells that were treated with 10–7 M 
1α,25(OH)2D3 or vehicle for 48 hours. Western blot analysis showing decreased level of 
cystatin D protein in CST5 shRNA cells. Scale bar: 20 μm. (B) CST5 knockdown abro-
gates the inhibition of cell proliferation by 1α,25(OH)2D3. Control shRNA and CST5 shRNA 
cells were treated with vehicle or 1α,25(OH)2D3 for the indicated times. Proliferation of 
cells in 1α,25(OH)2D3- versus vehicle-treated cultures is shown. (C) Quantitative RT-PCR 
analysis showing decreased CDH1 and CYP24 and increased LEF1 RNA expression in 
CST5 shRNA cells. (D) Western blot analysis showing changes in E-cadherin, c-MYC, 
and LEF-1 proteins in CST5 shRNA cells. (E) CST5 knockdown increases the expression 
of SNAI1 RNA (left) and protein (right). Numbers between the blots in A, D, and E corre-
spond to mean of the fold increase values obtained in 2 experiments.*P < 0.05, **P < 0.01, 
***P < 0.001. The Western blot in E shows noncontiguous lanes run on the same gel.
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Cystatin D proteins with reduced antiproteolytic activity maintain the 




















Ectopic cystatin D expression inhibits proliferation, migration, and anchorage-independent growth of HCT116 cells. (A) Cystatin D inhibits cell 
proliferation. (B) Cystatin D inhibits cell migration. HCT116 cells transfected with empty vector (Mock) or stably expressing CST5 were seeded 
in triplicate on Transwell filters, and 24 hours later migratory cells that had attached to the lower surface of filters were counted. Representative 
images and a quantification of data from 3 independent experiments are shown. Original magnification, ×200. (C) Cystatin D inhibits anchorage-
independent cell growth. Images of foci grown in semisolid agar and quantification are shown. Original magnification, ×63. ***P < 0.001.
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Cystatin D expression decreases in human colorectal tumorigenesis, in 


































































Cystatin D inhibits tumor growth in vivo. Immunodeficient mice were 
injected subcutaneously with (A) mock-transfected HCT116 cells or 
one of 2 clones of HCT116 cells transfected with CST5 (clone 9 or 20); 
or (B) mock-transfected LS147 T cells or one of 2 clones of LS147T 
cells transfected with CST5 (clone 9 or 11). The volume of the tumors 
generated was measured during the indicated period. Number of mice 
developing tumors at the end of the evaluation period: HCT116, mock: 
25 of 25, CST5: 5 of 26; LS174T, mock: 9 of 9, CST5: 9 of 21.
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Figure 7
Cystatin D induces an adhesive phenotype and represses genes involved in EMT. (A) Ectopic cystatin D induces intercellular adhesion. Phase-
contrast (left) and immunofluorescence and confocal microscope images (right) of control (Mock) and cystatin D–expressing HCT116 cells. Expres-
sion of E-cadherin, p120-catenin, and occludin proteins was analyzed using specific antibodies. Scale bars: 10 μm (left) and 20 μm (right). (B) 
Western blot analysis showing the induction of adhesion proteins by cystatin D in HCT116 cells. Numbers between the blots correspond to mean 
of the fold increase values obtained in 3 experiments. (C) Quantitative RT-PCR analysis showing increased levels of CDH1 RNA in cystatin D– 
expressing HCT116 cells. (D) Cystatin D represses EMT genes. Quantitative RT-PCR analysis of the expression of the EMT genes SNAI1, 
SNAI2/SLUG, TWIST, ZEB1, and ZEB2 in mock and cystatin D–expressing HCT116 cells.
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Cystatin D extends the cell cycle and inhibits of c-MYC expression and β-catenin/TCF transcriptional activity. (A) Cystatin D decelerates cell-
cycle entry. Mock and cystatin D–expressing HCT116 cell clones were stimulated with 10% serum to enter into cell cycle following synchro-
nization in G1 phase using double block with thymidine and mimosine as described in Methods, and the proportion of cells in each phase was 
estimated by flow cytometry. Asynchronously growing cells were used for comparison (black profile). Data from a representative experiment 
of 3 performed are shown. The bottom graph represents the mean percentage of cells present in each phase of the cell cycle (G1 in black, 
S in gray, and G2/M in white) 4 hours after release of the blockade. (B) Western blot analysis showing the decrease in c-MYC protein content 
in cells expressing exogenous cystatin D following the release of cell-cycle blockade. Numbers between the blots correspond to mean of the 
fold increase values obtained in 3 experiments. (C) The human c-MYC gene promoter is less active in cystatin D–expressing cells. Mock and 
2 cystatin D–expressing HCT116 cell clones were transfected with either of 2 constructs of the c-MYC promoter, and luciferase activity was 
measured 48 hours later. (D) β-Catenin/TCF transcriptional activity is reduced in cystatin D–expressing cells. Mock and 2 cystatin D–expressing 
HCT116 cell clones were transfected with the wild-type TOP-Flash and mutant FOP-Flash reporter plasmids, and the TOP/FOP ratio of luciferase 
activity was measured 48 hours later.
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Cystatin D mutant proteins with reduced anti-
proteolytic activity distinctly affect cell prolifera-
tion, migration, and gene expression. (A) West-
ern blot analysis showing the expression of 
CystD W108G and CystD W108G/Δ1–12 pro-
teins in SW480-ADH cells. (B) CystD W108G 
and CystD W108G/Δ1–12 have the same 
antiproliferative effect as wild-type cystatin D. 
(C) CystD W108G and CystD W108G/Δ1–12 
lack migration-inhibitory activity. (D) Effects of 
CystD W108G and CystD W108G/Δ1–12 on 
target genes. Western blot analysis showing 
E-cadherin, p120-catenin, and c-MYC protein 
expression in cells expressing mutant cystatin D 
proteins. Numbers between the blots in A and 
D correspond to mean of the fold increase val-
ues obtained in 3 experiments. (E and F) Quan-
titative RT-PCR analysis showing the RNA lev-
els of CDH1 and of SNAI1, ZEB1, and ZEB2 
in cells expressing either wild-type or mutant 
cystatin D proteins. ***P < 0.001.
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Cystatin D expression is downregulated during human colon cancer progression. (A) Immunohistochemical analysis of cystatin D and VDR expres-
sion in tissue microarrays. Counterstaining was with hematoxylin. Representative slices of nontumoral tissue and of well-, moderately, and poorly 
differentiated (differ.) carcinomas. Scale bar: 200 μm. (B) Quantification of cystatin D expression by estimation of staining intensity as described 
in Methods. The number of samples analyzed per group and the percentage corresponding to each level of cystatin D staining are shown.
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Cystatin D expression directly correlates with 
that of VDR and E-cadherin in colon carcino-
mas. (A) Representative Western blot showing 
the expression of cystatin D, VDR, and E-cad-
herin proteins in a series of matched normal 
(N) and tumoral (T) human colon tissues. (B) 
Top: Relationship between the log2 tumor ver-
sus normal (T/N) ratio of normalized protein 
levels of cystatin D and VDR or E-cadherin. 
Among the 32 sample pairs, the T/N ratio of 
cystatin D expression was less than 0.5 in 13 
samples; between 0.5 and 2 in 14 samples; 
and greater than 2 in 5 samples. Bottom: Box 
plot of the log2 T/N ratio of normalized VDR or 
E-cadherin expression in samples with high or 
low cystatin D levels in the colorectal cancer 
series. Boxes include values in the 25%–75% 
interval; internal lines represent the median; 
the outliers (circles) of the VDR and E-cad-
herin expression are indicated.
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Western blotting. Whole-cell  extracts were  prepared  by washing  the 
























































































Real-time RT-PCR. Cellular RNA levels of CST5, SNAI1, SNAI2/SLUG, 
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